Although subgroup analyses were limited by small sample sizes, clinical responses were not significantly influenced by baseline tumor BCMA and CD38 levels, MM cells in bone marrow, serum M protein or dose of infused CAR-Ts (Additional file 1: Fig. S7 and Table S3). Here, CD38 is linked to neoplasm.